Literature DB >> 11452934

Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system.

M A Grotzer1, B Geoerger, A J Janss, H Zhao, L B Rorke, P C Phillips.   

Abstract

BACKGROUND: Primitive neuroectodermal tumors (PNET) of the central nervous system, including medulloblastomas, are the most common malignant brain tumors of childhood. Whereas some patients experience prolonged disease control after surgery and adjuvant therapy, others with tumors that appear comparable will relapse and eventually die from progressive disease. PROCEDURE: Because proliferative activity may provide a potential correlate of biologic aggressiveness, PNETs of 78 well-characterized patients were evaluated by Ki-67 (MIB-1) immunohistochemistry. Proliferation indices (PI) were determined by counting Ki-67 (MIB-1) positive tumor cells either in the highest staining region (hot spot PI), or in at least 15 randomly chosen fields (random PI).
RESULTS: Twenty-five of 78 PNETs showed amore than twofold higher value of hot spot PI (median 9.3%; range 0.6-56%), compared to random PI (median 5.6%; range 0.2-41.3%), Univariate Cox regression analysis revealed that PNETs with a high hot spot PI had a significantly greater risk of progression and death than PNETs with a low hot spot PI (hazard ratio 1.58, P = 0.04). The hazard ratio remained significant after adjusting for M-stage in multivariate analysis. In contrast to hot spot PI, random PI proved not to be a significant prognostic predictor.
CONCLUSIONS: Hot spot PI is a significant and independent prognostic factor in PNETs. Its assessment is uncomplicated, reliable, and may supplement routine histologic examination as a means for improving the accuracy of predicting the biologic behavior of childhood PNETs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11452934     DOI: 10.1002/1096-911X(20010201)36:2<268::AID-MPO1064>3.0.CO;2-F

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  8 in total

1.  Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report.

Authors:  Thomas Krampulz; Volkmar H Hans; Falk Oppel; Uwe Dietrich; Maximilian J A Puchner
Journal:  J Neurooncol       Date:  2006-03-10       Impact factor: 4.130

2.  Medulloblastoma.

Authors:  Catherine A. Mazzola; Ian F. Pollack
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 3.  A review of clinical and histological features of Spanish paediatric medulloblastomas during the last 21 years.

Authors:  Alejandro Urberuaga; Aurora Navajas; Juan Burgos; José Ignacio Pijoán
Journal:  Childs Nerv Syst       Date:  2005-11-09       Impact factor: 1.475

4.  Medulloblastoma: clinicopathologic evaluation of 42 pediatric cases.

Authors:  Yeşim Ertan; Murat Sezak; Bengü Demirağ; Mehmet Kantar; Nazan Cetingül; Tuncer Turhan; Yusuf Erşahin; Saffet Mutluer; Yavuz Anacak; Taner Akalin
Journal:  Childs Nerv Syst       Date:  2009-01-13       Impact factor: 1.475

Review 5.  Advances in treatment of pediatric brain tumors.

Authors:  Patricia L Robertson
Journal:  NeuroRx       Date:  2006-04

6.  Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression.

Authors:  Andrey Korshunov; Marina Savostikova; Sergey Ozerov
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

7.  Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir.

Authors:  Marieke Gringmuth; Jenny Walther; Sebastian Greiser; Magali Toussaint; Benjamin Schwalm; Marcel Kool; Rolf-Dieter Kortmann; Annegret Glasow; Ina Patties
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

8.  Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma.

Authors:  U Tabori; V Wong; J Ma; M Shago; N Alon; J Rutka; E Bouffet; U Bartels; D Malkin; C Hawkins
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.